Does Sotatercept-Winrevair require long-term treatment?

Sotatercept-Winrevair is an innovative targeted drug for adults with pulmonary arterial hypertension (PAH). Its mechanism of action mainly improves vascular remodeling and cardiopulmonary function by inhibiting the activin signaling pathway. PAH is a chronic, progressive disease, and there may be a risk of symptom persistence or disease progression even with standard drug treatment. Therefore, soltecept usually requires long-term continuous use to maintain its vasoprotective effects and exercise tolerance-improving effects.

Clinical studies have shown that long-term use of Sotecept can stabilize patients'6-minute walking distance (6MWD), improve NT-proBNP levels, and have a positive impact on right heart function. Since vascular remodeling and cardiac function damage are persistent in patients with PAH, short-term medication is difficult to produce a lasting intervention in the course of the disease. Therefore, long-term maintenance therapy is the key to ensuring efficacy. During the follow-up period of several months to more than one year, the patients who used Sotercept in the study continued to have significant effects and no obvious resistance appeared, which shows that long-term administration is feasible and controllable.

In addition, long-term medication needs to be combined with regular monitoring, such as blood pressure, liver and kidney function, and blood routine, to ensure drug safety. For some patients, doctors may adjust the dose or combine it with other PAH drugs based on improvement of the condition to optimize the treatment effect. Long-term treatment can not only sustainably improve exercise capacity, but also slow down the process of pulmonary vascular remodeling, thereby delaying disease progression and cardiac function decline.

To sum up, as an innovative targeted drug for adult PAH, sotercept (Winrevair) has significant clinical significance in its long-term use. Continuous medication can maintain exercise capacity, improve quality of life, and delay disease progression with controllable safety, providing a new option for long-term management of adult PAH patients.

Reference materials:https://www.drugs.com/mtm/sotatercept.html